CGEM- Cullinan Therapeutics, Inc.

Name: Cullinan Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Cullinan Therapeutics, Inc. (CGEM) has 13 insiders with recent SEC Form 4 filings, including 8 buys and 8 sells. CGEM is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	Lynx1 Capital Management LP	8.96M	$130.91M	-
CEO	Ahmed Nadim	420.7K	$6.14M	-
Other	Jones Jeffrey Alan	169.5K	$2.48M	-
Other	Sumer Jacquelyn L	135.4K	$1.98M	-
Other	Michaelson Jennifer	132.6K	$1.94M	-

Activity

Buys and sells only

Transactions

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Dec 23, 2025	Ahmed Nadim49	President And CEO	Sell	9,922	$10.01	$99,319.22	-2.3%	+28.4%	-
Dec 19, 2025	Michaelson Jennifer65	Chief Scientific Officer	Sell	1,345	$10.01	$13,463.45	-1.0%	+35.1%	-
Dec 18, 2025	Michaelson Jennifer65	Chief Scientific Officer	Sell	2,898	$9.67	$28,023.66	-2.1%	+31.6%	-
Dec 18, 2025	Sumer Jacquelyn L	Chief Legal Officer	Sell	3,480	$9.67	$33,651.60	-2.5%	+31.6%	-
Dec 18, 2025	Jones Jeffrey Alan	Chief Medical Officer	Sell	4,632	$9.67	$44,791.44	-2.7%	+31.6%	-
Dec 15, 2025	Michaelson Jennifer65	Chief Scientific Officer	Sell	3,143	$12.23	$38,432.74	-1.1%	+29.7%	-
Nov 24, 2025	Michaelson Jennifer65	Chief Scientific Officer	Sell	4,000	$12.30	$49,200.00	-2.8%	+8.2%	-
Oct 28, 2025	Lynx1 Capital Management LP45	10% Owner	Buy	165,667	$8.40	$1,391,685.63	+1.9%	+41.0%	-
Oct 17, 2025	Lynx1 Capital Management LP45	10% Owner	Buy	248,749	$8.46	$2,103,912.01	+0.7%	+35.7%	-
Oct 10, 2025	Lynx1 Capital Management LP45	10% Owner	Buy	1,459,641	$6.73	$9,826,941.41	+6.3%	+50.5%	-

Page 1Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC